The current dosage of zidovudine for children is 180 mg/m2 every 6 h. To investigate whether a lower dosage was equally effective, human immunodeficiency virus (HIV)-infected children (3 months to 12 years) with mild to moderate symptoms were randomly assigned to receive either high-dose (180 mg/m2/dose) or low-dose (90 mg/m2/dose) zidovudine (double-blind). Treatments were compared with respect to neuropsychologic function, survival, clinical and laboratory evidence of disease progression, and safety and tolerance. Four hundred twenty-six HIV-infected children were enrolled; median time for receipt of study drug was 35 months. Zidovudine in either dose was well tolerated, with no difference in efficacy or tolerance by treatment group using...
To produce concentrations of zidovudine (AZT) in plasma and cerebrospinal fluid that would provide c...
OBJECTIVE: To evaluate the effect of the antimicrobial agent trimethoprim/sulphamethoxazole (TMP/SMX...
WHO 2013 guidelines recommend universal treatment for HIV-infected children younger than 5 years. No...
Objective: To evaluate the clinical, immunologic, and virologic response to indinavir, zidovudine, a...
OBJECTIVES: Zidovudine is often administered every 12 h in HIV-infected children, but so far no phar...
Context Although protease inhibitors are used routinely in adults with human immunodeficiency virus ...
Data on zidovudine pharmacokinetics in children dosed using World Health Organization weight bands a...
Data on zidovudine pharmacokinetics in children dosed using World Health Organization weight bands a...
Abstract OBJECTIVE: To evaluate the clinical, immunologic, and virologic response to indinavir, zid...
Resistance to zidovudine (3'-azido-3'-deoxythymidine) and 2',3'-dideoxyinosine (...
BACKGROUND: Alternatives to the available stavudine-containing paediatric fixed-dose combination (FD...
Zidovudine reduces the rate of vertical transmission of HIV in non-breastfed populations. We assesse...
BACKGROUND: Lopinavir/ritonavir is a common protease inhibitor (PI) used for second-line regimens in...
Contains fulltext : 164754.pdf (publisher's version ) (Open Access)BACKGROUND: WHO...
Objective: To evaluate the clinical, immunologic, and virologic response to indinavir, zidovudine, a...
To produce concentrations of zidovudine (AZT) in plasma and cerebrospinal fluid that would provide c...
OBJECTIVE: To evaluate the effect of the antimicrobial agent trimethoprim/sulphamethoxazole (TMP/SMX...
WHO 2013 guidelines recommend universal treatment for HIV-infected children younger than 5 years. No...
Objective: To evaluate the clinical, immunologic, and virologic response to indinavir, zidovudine, a...
OBJECTIVES: Zidovudine is often administered every 12 h in HIV-infected children, but so far no phar...
Context Although protease inhibitors are used routinely in adults with human immunodeficiency virus ...
Data on zidovudine pharmacokinetics in children dosed using World Health Organization weight bands a...
Data on zidovudine pharmacokinetics in children dosed using World Health Organization weight bands a...
Abstract OBJECTIVE: To evaluate the clinical, immunologic, and virologic response to indinavir, zid...
Resistance to zidovudine (3'-azido-3'-deoxythymidine) and 2',3'-dideoxyinosine (...
BACKGROUND: Alternatives to the available stavudine-containing paediatric fixed-dose combination (FD...
Zidovudine reduces the rate of vertical transmission of HIV in non-breastfed populations. We assesse...
BACKGROUND: Lopinavir/ritonavir is a common protease inhibitor (PI) used for second-line regimens in...
Contains fulltext : 164754.pdf (publisher's version ) (Open Access)BACKGROUND: WHO...
Objective: To evaluate the clinical, immunologic, and virologic response to indinavir, zidovudine, a...
To produce concentrations of zidovudine (AZT) in plasma and cerebrospinal fluid that would provide c...
OBJECTIVE: To evaluate the effect of the antimicrobial agent trimethoprim/sulphamethoxazole (TMP/SMX...
WHO 2013 guidelines recommend universal treatment for HIV-infected children younger than 5 years. No...